KLRK1 and acute myeloid leukemia: Additionally, treatment with decitabine for 28 days increases natural killer (NK) cell-mediated lysis of AML cells and increases expression of the killer cell lectin-like receptor K1 (KLRK1) ligand on tumor cells (Li et al., 2017; Tang et al., 2008).